news flash·2025-06-17 08:51Core Viewpoint - The company received approval from the European Medicines Agency (EMA) for a new manufacturer of Enoxaparin Sodium Injection, enhancing its production capacity and market competitiveness [1] Group 1: Approval Details - The approved product is Enoxaparin Sodium Injection, marketed under the name Inhixa [1] - The injection comes in various specifications: 20mg/0.2ml, 40mg/0.4ml, 60mg/0.6ml, 80mg/0.8ml, 100mg/1ml, 120mg/0.8ml, and 150mg/1ml [1] - The new manufacturer is Shenzhen Hepalink Pharmaceutical Group Co., Ltd., located at No. 1 Rongtian Road, Kengzi Street, Pingshan District, Shenzhen, China [1] Group 2: Strategic Implications - The approval will support the company's strategy for internationalization of its formulations [1] - It will provide sufficient production capacity to enhance the company's competitiveness in the market [1]